Insights
Independent analysis of company developments, industry trends, and capital markets, with a focus on undercovered public companies. We examine what changed, why it matters, and the implications for investors.
Topics
88 insights
Biotechnology & HealthcareSELLAS Reports a Survival Benefit in AML as Its Cancer Vaccine Approaches FDA Review
SELLAS Life Sciences reported that its investigational cancer vaccine met the overall-survival endpoint in a Phase 3 trial of patients with acute myeloid leukemia who had reached a second or later remission and could not undergo a donor stem cell transplant. Median survival was 24.0 months with galinpepimut-S versus 14.7 months with investigator-selected care. The result provides a basis for a planned FDA discussion, while detailed control-arm, safety and secondary-endpoint data remain important to interpretation. SELLAS ended September with $134.7 million in cash after substantial warrant exercises.
Biotechnology & HealthcareHelus Pharma’s Depression Trial Succeeds as Safety and Funding Questions Move Forward
Helus Pharma’s HLP003 met the primary endpoint in its first pivotal depression trial, producing a 7.6-point advantage over placebo on a symptom scale at six weeks. Patients remained on their existing antidepressants, and the benefit persisted at the study’s 12-week assessment. The results strengthen the case for an intermittent add-on treatment, although the nature of three treatment-related serious adverse events remains undisclosed. Quarterly filings show $171.1 million in cash at September 30 and continued clinical spending ahead of a second pivotal readout expected in late 2027.
Biotechnology & HealthcareAmylyx’s Detailed Avexitide Results Bring a Rare Post-Surgery Condition Closer to Treatment
Amylyx has released detailed Phase 3 results for avexitide, an experimental daily injection for recurrent low blood sugar after gastric bypass. In 78 adults receiving dietary management, the treatment reduced the rate of specified hypoglycemic events over 16 weeks versus placebo. The company plans to seek U.S. approval by year-end and prepare for a possible 2027 launch. The study provides a clearer picture of the potential benefit, while diagnosis, insurance access, the approved patient population and sustained treatment will determine the commercial opportunity.
Biotechnology & HealthcareMilestone Extends Its Cash Runway as CARDAMYST’s Early Sales Lag Launch Costs
Milestone Pharmaceuticals plans to cut operating expenses by approximately 30% as it develops a second potential use for CARDAMYST, its newly launched heart-rhythm nasal spray. Third-quarter product sales reached $963,000, while a separate $2 million licensing milestone accounted for most reported revenue. Management expects its cash to support operations into late 2028, around the time of a Phase 3 readout. Investors must weigh improving prescription activity and insurance coverage against launch spending, sales-based financing obligations and the time needed to establish a sustainable commercial business.
Mining & Critical MineralsAtalaya Adds Two Spanish Copper Projects as Its Growth Pipeline Competes for Capital
Atalaya Mining has acquired the former Tharsis and La Zarza mines in southern Spain for €125 million, adding large copper-bearing resources to a portfolio already led by its operating Riotinto complex and the proposed Touro development. The purchase follows a quarter of record EBITDA, helped by higher copper prices and increased sales. Although Atalaya paid €75 million upfront from cash, another €50 million is due within a year. The value of the expansion will depend on permitting, processing economics and how the new assets fit alongside existing investment priorities.
Biotechnology & HealthcareKura’s Leukemia Drug Sales Grow as Partnership and Financing Shape Future Returns
Kura Oncology’s first commercial medicine generated $13.9 million in third-quarter sales as more patients began treatment for a genetically defined form of acute myeloid leukemia. The launch is gaining traction, but Kura shares U.S. commercialization profits and losses with Kyowa Kirin and continues to fund extensive clinical development. A new Oberland Capital financing provides capital now and conditional access to more, alongside debt, equity issuance and a future sales-based obligation. The opportunity to treat newly diagnosed patients is larger than the current indication, but evidence from a Phase 3 program is not expected until 2028.
EnergyRWE and KKR Share Capital Commitments as £12 Billion Wind Projects Advance
RWE and KKR have completed their partnership and secured financing for two British offshore wind farms requiring approximately £12 billion of investment. Each partner will own half of the projects, while RWE leads construction and delivery. Long-term power contracts provide greater revenue visibility, and project-level financing will help support development through expected commissioning in 2030. For investors, the transaction shares RWE’s capital commitments but leaves important details undisclosed, including the partners’ individual contributions. Construction costs, timing and electricity generation will determine how much value the projects ultimately deliver.
Biotechnology & HealthcarePepGen’s DM1 Trial Shows Early Functional Improvements as Safety and FDA Questions Remain
PepGen reported that six patients receiving its experimental myotonic dystrophy treatment showed an average 46.5% correction on a muscle RNA measure, alongside improvements in hand opening and other functional tests. The Phase 2 findings support continued development, but the small cohort and short follow-up limit conclusions about clinical benefit. Earlier kidney-related findings and a U.S. partial clinical hold remain relevant as the company studies higher and longer dosing. A larger trial must show that molecular changes translate into durable improvements meaningful to patients.
Mining & Critical MineralsMeridian’s Cabaçal Financing Offers Advance a Mine With Important Terms Unsettled
Meridian Mining has appointed an engineering and construction management contractor for its Cabaçal copper-gold project in Brazil and received indicative financing proposals, including packages totaling $400 million. The project’s feasibility study models a $2.09 billion after-tax net present value, but its initial capital estimate relies on tax credits and excludes financing charges. The financing offers remain subject to negotiation, while the mine installation permit was under review in the October technical report. The crucial issue for investors is how much of the modeled project value Meridian can retain after construction funding, sales arrangements and other obligations are settled.
EnergyCentrus’s $7 Billion Backlog Depends on Building Its Uranium Enrichment Capacity
Centrus Energy has started shipping centrifuges for a proposed expansion of U.S. uranium-enrichment capacity. Its $7.0 billion backlog signals substantial potential demand, but includes $5.4 billion of contingent sales commitments and government contract options that may not be exercised. Quarterly net income also benefited from a noncash warrant gain. A strong cash balance gives Centrus resources to advance construction, while milestone payments, financing terms and the cost of bringing capacity online will determine how much of the opportunity reaches shareholders.
Biotechnology & HealthcareRigel’s VEPPANU Launch Adds Growth, With Royalties and Costs Still to Absorb
Rigel Pharmaceuticals has begun selling VEPPANU, an oral treatment for a defined group of patients with advanced breast cancer. The drug generated $6.6 million in net sales in its first partial quarter, providing most of Rigel’s year-over-year product sales growth in the third quarter. The company’s 2026 revenue guidance excludes the new medicine, making the established portfolio’s performance and launch sales separate measures. Royalties, development commitments and commercialization costs will determine how much of VEPPANU’s revenue Rigel retains as profit.
Industrials & AerospaceAdvanSix’s Rising Sales Mask Weaker Earnings as Ammonia Expansion Advances
AdvanSix reported higher third-quarter sales as it passed through rising raw-material costs, but lower production and input inflation reduced earnings. The U.S. manufacturer supplies nylon materials, fertilizers and industrial chemicals through an integrated network. Quarterly cash flow improved with help from working-capital movements, while free cash flow remained negative for the first nine months. A proposed federal grant could support a multiyear ammonia expansion. The company’s near-term cash position depends on customer advances, spending and operating performance, while the expansion remains subject to federal review.